Monoclonal antibody · Inhibitor of programmed cell death protein 1 (PD-1) (PDCD1) · developed by Incyte
Retifanlimab is a humanized monoclonal antibody that binds the PD-1 receptor on T cells and blocks its interaction with the ligands PD-L1 and PD-L2, potentiating T-cell activity against tumors. It is studied in resectable sarcoma.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 18, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04374305 | Phase 2 | Neurofibromatosis Type 2 | Recruiting | INCY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Resectable Sarcoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the INCY page.
See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INCY catalysts and pipeline →